http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2004058295-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate | 2003-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2004058295-A1 |
| titleOfInvention | Treatment for pemphigoid |
| abstract | A therapeutic agent for pemphigus is provided. To use IFN-γ as a therapeutic agent for pemphigoid, 2 million JRU is intravenously administered once a day for 7 days. Depending on the symptoms, side effects, and age, the dosage can be changed or it can be changed to intravenous infusion once every few days. IFN-γ is considered to be effective against pemphigoid, with almost no side effects. The mechanism of action is presumed to suppress migration and function against eosinophils, which are thought to be directly involved in the development of pemphigoid. |
| priorityDate | 2002-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 137.